HIPEC vs Chemotherapy for Ovarian Cancer?

These are not competing alternatives. HIPEC is a one time treatment given during surgery, delivering heated chemotherapy directly into the abdominal cavity to target microscopic disease left on the peritoneal surfaces. Systemic chemotherapy is given intravenously over several cycles across months, treating the whole body, including disease outside the abdomen. Most patients receiving HIPEC also receive systemic chemotherapy before and after surgery. HIPEC is typically an addition, not a substitute.

According to Dr. Sandeep Nayak, Surgical Oncologist in India, “These two treatments answer different needs, and I want patients to understand that clearly. Systemic chemotherapy circulates through the bloodstream and reaches the whole body. HIPEC stays localised, delivered once, directly into the abdominal cavity during surgery, to clean up microscopic disease that surgery alone cannot remove. In practice, a patient having HIPEC is almost always also having systemic chemotherapy. One does not replace the other.”

Understanding the distinct role of each treatment clarifies why they are typically used together.

• HIPEC’s role : Delivered once, during surgery, HIPEC targets microscopic tumour cells remaining on the peritoneal surfaces after visible disease is removed.
• Chemotherapy’s role : Given intravenously across multiple cycles, systemic chemotherapy reaches disease anywhere in the body, not just within the abdominal cavity.
• Different reach : HIPEC stays confined to the peritoneal cavity where it is administered, while chemotherapy circulates through the entire bloodstream.
• Different timing : Chemotherapy is given over months in separate sessions, while HIPEC is delivered in a single procedure at the time of surgery.

This distinction underpins effective ovarian cancer treatment, where the two approaches are coordinated rather than chosen between.

Here is how the two treatments line up side by side.

• When HIPEC applies : HIPEC is added specifically during interval cytoreductive surgery, where trial evidence supports its benefit alongside chemotherapy.
• When chemotherapy alone applies : Many patients receive systemic chemotherapy without HIPEC, particularly when surgery is not part of the immediate plan.
• Not interchangeable : Choosing one over the other is not how this decision works. The disease pattern and surgical plan determine what is added.
• A combined approach : The strongest evidence supports HIPEC as a complement to standard chemotherapy, not as a stand alone alternative.

This combined approach is explored further in our guide to ovarian cancer treatment options, which covers how these therapies fit into the overall treatment plan.

Dr. Sandeep Nayak is a surgical oncologist with 24 years of experience and a fellowship in laparoscopic and robotic onco-surgery. His approach to advanced ovarian cancer integrates cytoreductive surgery, HIPEC where indicated, and coordination with medical oncology for systemic chemotherapy, treating these as complementary components of one plan rather than competing choices. This coordinated approach reflects how the strongest evidence for HIPEC is applied in practice.

Advanced ovarian cancer treatment works best as a coordinated sequence rather than a choice between options. Systemic chemotherapy addresses disease throughout the body, surgery removes what can be seen, and HIPEC, where appropriate, addresses what remains microscopically at the surgical site. Understanding how these three elements work together, rather than viewing them as competitors, is what allows a treatment plan to address the disease as fully as current evidence supports.

References

1. OVHIPEC trial results on HIPEC in ovarian cancer — National Library of Medicine
2. Systemic chemotherapy standards in ovarian cancer — National Library of Medicine

Disclaimer: This blog is for informational and educational purposes only and is not a substitute for professional medical advice or diagnosis.